Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.

Rajagopalan K, O'Day K, Meyer K, Pikalov A, Loebel A.

J Med Econ. 2013 Aug;16(8):987-96. doi: 10.3111/13696998.2013.809353. Epub 2013 Jun 21.

PMID:
23742620
2.

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.

Rajagopalan K, Hassan M, O'Day K, Meyer K, Grossman F.

J Med Econ. 2013 Jul;16(7):951-61. doi: 10.3111/13696998.2013.807813. Epub 2013 Jun 7.

PMID:
23701260
3.

Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study.

Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM.

Schizophr Res. 2013 Jun;147(1):95-102. doi: 10.1016/j.schres.2013.03.013. Epub 2013 Apr 11.

4.

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.

Loebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD.

CNS Spectr. 2014 Apr;19(2):197-205. doi: 10.1017/S1092852913000904. Epub 2013 Dec 13.

5.

Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension.

Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1373-82. doi: 10.1016/j.euroneuro.2013.08.003. Epub 2013 Aug 27.

PMID:
24035633
6.

Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.

Locklear JC, Alemayehu B, Brody RS, Chavoshi S, Tunceli O, Kern D, Earley WR.

Clin Ther. 2013 Dec;35(12):1923-32. doi: 10.1016/j.clinthera.2013.10.005. Epub 2013 Nov 22.

PMID:
24275622
7.

Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis.

Locklear JC, Wahlqvist P, Gustafsson U, Udd M, Fajutrao L, Eriksson H.

J Comp Eff Res. 2014 Jul;3(4):335-44. doi: 10.2217/cer.14.27.

PMID:
25275231
8.

Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.

Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG.

Schizophr Res. 2013 Apr;145(1-3):101-9. doi: 10.1016/j.schres.2013.01.009. Epub 2013 Feb 13.

9.

Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.

Woodward TC, Tafesse E, Quon P, Lazarus A.

Pharmacoeconomics. 2010;28(9):751-64. doi: 10.2165/11538350-000000000-00000.

PMID:
20623994
10.

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US.

O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A.

Clinicoecon Outcomes Res. 2013 Sep 13;5:459-70. doi: 10.2147/CEOR.S47990. eCollection 2013.

11.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
12.
13.

Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia.

Järbrink K, Kreif N, Benedict A, Locklear J.

Curr Med Res Opin. 2009 Mar;25(3):709-16. doi: 10.1185/03007990902738810 .

PMID:
19196221
14.

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Edwards NC, Locklear JC, Rupnow MF, Diamond RJ.

Pharmacoeconomics. 2005;23 Suppl 1:75-89.

PMID:
16416763
15.

Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.

Rajagopalan K, Meyer K, O'Day K, Denno M, Loebel A.

J Med Econ. 2015;18(10):821-7. doi: 10.3111/13696998.2015.1052462. Epub 2015 Jul 27.

PMID:
25985265
16.
17.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
18.

Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.

Knapp M, Locklear J, Järbrink K.

Curr Med Res Opin. 2009 Jul;25(7):1593-603. doi: 10.1185/03007990903010623.

PMID:
19469696
20.

Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study.

Peuskens J, Trivedi JK, Brecher M, Miller F; Study 4 Investigators.

Int Clin Psychopharmacol. 2010 May;25(3):183-7. doi: 10.1097/YIC.0b013e328337789b.

PMID:
20216222
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk